Xiaoqing Yu

5PUBLICATIONS
32CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 20, 2026
Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.

Ling Xie, Chunwei Xu, Han Si

|Sep 19, 2023
Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.

Kaiyan Chen, Yanjun Xu, Zhiyu Huang

|Nov 22, 2022
Real-world treatment and prognostic factors for survival in ALK+ non-small cell lung cancer (NSCLC) patients with brain metastases in China.

Na Li, Mingying Xie, Zichao Zhou

|Nov 16, 2022
The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.

Xiaoqing Yu, Jinfei Si, Jingwen Wei

|Oct 01, 2021
Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.

Jiamin Sheng, Hui Li, Xiaoqing Yu

Pageof 1

Frequent Collaborators

3 joint publications

Yun Fan

2 joint publications

Jiamin Sheng

2 joint publications

Kaiyan Chen

2 joint publications

Mingying Xie